Please ensure Javascript is enabled for purposes of website accessibility

Why Cempra Inc. Got Crushed Again

By Brian Orelli, PhD - Nov 2, 2016 at 4:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech isn't having a good week.

Image source: Getty Images.

What happened

After falling 21% on Friday following the announcement of delays due to issues at its contract manufacturer, Cempra (MLNT) fell another 61% today after the U.S. Food and Drug Administration released briefing documents expressing concerns over the safety of Cempra's lead pneumonia antibiotic, solithromycin.

So what

Specifically the FDA is worried about potential liver damage, which is measured by liver enzyme levels. Two patients discontinued the drug due to elevated liver enzyme levels, although the FDA notes that "elevations in the majority of patients appeared to be asymptomatic and generally transient."

Cempra's biggest problem appears to be that the longer patients are treated with solithromycin, the more likely they are to experience liver damage, suggesting that the signal is real. Of the two phase 3 trials, the one with the longer exposure had an increased incidence of elevated liver enzymes. And when Cempra tested solithromycin as a treatment to reduce airway inflammation in patients with the lung disease COPD for 28 days, three of the four patients had elevated liver enzymes.

All told, the FDA review sums things up in a less-than-stellar way for Cempra: "We conclude that these findings comprise a genuine liver injury signal."

Now what

The FDA's Antimicrobial Drugs Advisory Committee meeting is scheduled for Friday, when outside experts will look at the FDA's conclusions and Cempra's explanation and give their opinions of the data. There are risks with every drug, so the main issue will be whether the need for new antibiotics justifies the added potential risk of liver damage.

Keep in mind that the FDA has the final say, so even if the committee recommends approval of solithromycin, the agency could still give it a thumbs-down.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Melinta Therapeutics, Inc. Stock Quote
Melinta Therapeutics, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.